Development and external validation of an admission-based model for 180-day mortality in diabetic acute myocardial infarction
Frontiers in Endocrinology · 02.07.2026 · 17
DOI: 10.3389/fendo.2026.1891663 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Frontiers in Endocrinology, online erschienen am 02.07.2026. Verfasst von Yanlong Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Myocardial Infarction, Diabetes Mellitus, Patient Admission. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients with diabetes mellitus and acute myocardial infarction (DM-AMI) are at high risk, but risk heterogeneity within this subgroup remains insufficiently characterized. Whether a parsimonious admission-based model provides prognostic information beyond GRACE remains uncertain. We aimed to assess admission risk heterogeneity in DM-AMI and develop and externally validate a model for 180-day mortality using routine variables.
Methods
This retrospective dual-cohort study included AMI patients from a Beijing tertiary hospital (development cohort) and an ICU-based MIMIC-IV cohort (external validation). A Cox model was built using admission variables. Model performance was evaluated using discrimination, calibration, and decision curve analysis with internal bootstrap validation and comparison with GRACE.
Results
Among 4,167 patients, 1,514 had DM-AMI with 90 deaths at 180 days. The model included eight variables (age, heart rate, SBP, glucose, BUN, hemoglobin, RDW, WBC). It showed good discrimination in the development cohort (C-index 0.848; AUC 0.857) and maintained performance externally (AUC 0.744). GRACE comparison showed similar discrimination, while the combined model improved performance (ΔAUC = 0.014, P = 0.031). Calibration in MIMIC-IV indicated risk overestimation (slope 0.527; O/E 0.652).
Conclusion
DM-AMI patients exhibit marked admission risk heterogeneity. The model provides complementary prognostic information beyond GRACE but requires recalibration for absolute risk use in external settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Emergency, Xuanwu Hospital, Capital Medical University, Beijing, China.
- Department of Medical Care, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Zitieren
APA
Zhao, Y., Jiang, H., Zhao, Y., Wang, S., Yu, Q., Zeng, J., Xie, S., Li, J., & Liu, Z. (2026). Development and external validation of an admission-based model for 180-day mortality in diabetic acute myocardial infarction. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1891663
Vancouver
Zhao Y, Jiang H, Zhao Y, Wang S, Yu Q, Zeng J, et al. Development and external validation of an admission-based model for 180-day mortality in diabetic acute myocardial infarction. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1891663
BibTeX
@article{Zhao2026,
author = {Zhao, Yanlong and Jiang, Haodong and Zhao, Yuanyuan and Wang, Shuai and Yu, Qicheng and Zeng, Jing and Xie, Shan and Li, Jiatong and Liu, Zhi},
title = {Development and external validation of an admission-based model for 180-day mortality in diabetic acute myocardial infarction},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.1891663}
}
EUVIMED